Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 3/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | DUSP5 | Q16690 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677235 | 0.98 | NT5E (0.65) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL2928135 | 0.98 | NT5E (0.65) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL29677298 | 0.98 | NT5E (0.65) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL28019677 | 0.89 | NT5E (0.54) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL9805944 | 0.88 | NT5E (0.71) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL564556 | 0.88 | NT5E (0.71) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL9340309 | 0.86 | NT5E (0.65) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL564558 | 0.86 | NT5E (0.74) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL11502500 | 0.86 | NT5E (0.74) | NT5EPRMT1PTPN1APEX1CYP1A2 | |
| SCHEMBL66310 | 0.86 | NT5E (0.74) | NT5EPRMT1PTPN1APEX1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8377992-B2 | TRBD-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100160260-A1 | TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | NT5E 1016/4885PRMT1 774/4885PTPN1 2426/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | NT5E 1016/4885PRMT1 774/4885PTPN1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.